Argatroban is a synthetic thrombin inhibitor that acts independently of any cofactor. It inhibits free as well as fibrin- and clot-bound thrombin. The clinical history of two patients is presented, both with previous allergic reactions toward heparin and hirudin. In both patients, antibodies against hirudin were documented. Argatroban was successfully used in both patients without any side effects. We conclude argatroban to be the drug of choice in patients with intolerance to heparin and hirudin. Moreover, genetic variations affecting the hepatic catabolism of argatroban might exist, because very different dosages of argatroban were needed in the two patients.
Lewis BE, Walenga JM. Clinical use of argatroban. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. Marcel Dekker, Inc., New York, NY; 2003:185.
2.
Banner DW, Hadvary P.Inhibitor binding to thrombin with x-ray crystallographic studies. Adv Exp Med Biol1993;340:27.
3.
Bauer M, Brandstetter H, Turk D, et al.Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin Thromb Hemost1993;19:352.
4.
Hursting MJ, Alford KL, Becker JC, et al.Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin Thromb Hemost1997;23:503.
5.
Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev1991;9:247.
6.
Hijikate Okunomiya A, Okamoto S.A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost1992;18:135.
7.
Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy2000;20:318.
8.
Ahmad S, Ahsan A, Iqbal O, et al.Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: implications in the monitoring and dosage optimization in cardiovascular patients. Clin Appl Thromb Hemost1998;4(4):243.
9.
Lewis BE, Wallis DE, Berkowitz SD, et al.for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation2001;103:1838.
